The European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO) and the International Osteoporosis Foundation (IOF) have awarded the ESCEO-IOF Pierre Delmas Medal to Professor Bruno Sepodes, PharmD MSc PhD MPH, Full Professor of Pharmacological Sciences at the Faculty of Pharmacy of the University of Lisbon (Portugal), and Chair of the  EMAs Committee for Human Medicinal Products (CHMP).

The ESCEO-IOF Pierre Delmas Medal was presented at the Opening Ceremony of the World Congress on Osteoporosis, Osteoarthritis and Musculoskeletal Diseases, taking place in Prague, Czech Republic, from April 16 to 19, 2026. The award recognizes an individual who has made outstanding and major scientific contributions to the study of bone and mineral diseases. It is named after the late Professor Pierre Delmas, Co-Founder and First President of IOF, who was Professor of Medicine and Rheumatology at the University of Lyon, France, Director of the INSERM research unit ‘Pathophysiology of Osteoporosis’, and an outstanding scientist who directed essential basic and clinical research in metabolic bone diseases.

About Professor Bruno Sepodes, PharmD MSc PhD MPH

Bruno Sepodes is a Full Professor of Pharmacological Sciences at the Faculty of Pharmacy of the University of Lisbon (Portugal). He is a Pharmacist (holding a PharmD), holds an MSc in Pharmaceutical Regulatory Science, a PhD in Pharmacology and Habilitation in Pharmacology and Pharmacotherapy, all by the University of Lisbon. Bruno also holds a MPH degree from the Bloomberg School of Public Health of Johns Hopkins University (USA). Besides being Senior Non-Clinical and Clinical Expert for INFARMED (the Portuguese National Authority for Medicines and Health Products), he became a member of the European Medicines Agency’s Committee for Orphan Medicinal Products (COMP) in 2008, serving two mandates as Chairperson of this Committee (2012-2018). Additionally, Bruno is also member of the European Medicines Agency’s (EMA) Committee for Human Medicinal Products (CHMP, since 2012) and was a member of the Committee of Advanced Therapies (CAT, 2013-2024). In 2024, Bruno Sepodes became Chair of the Committee of Human Medicinal Products (CHMP), following two mandates as Vice-Chair of the committee (2018-2024). During 2020 Bruno became a member of the EMA Emergency Task Force (ETF), representing CHMP in the efforts to deal with the challenges of COVID-19 pandemic therapeutics and vaccines, and, in 2022, with the extension of the mandate of EMA and formal implementation of ETF as a constant working force of the Agency, Bruno became Co-Chair of the EMA Emergency Task Force. In 2018, he received the “EURORDIS Leadership Black Pearl Award” for Rare Diseases, awarded to an individual who has demonstrated remarkable leadership in the field of rare diseases at a European level.

Bruno received 15 national and international scientific awards and was among the top 100 inspirational industry professionals on “The Medicine Maker Power List 2018”, under the category ‘Masters of Change’ for 2018. He is an author and co-author of several scientific publications in international journals and has presented at national and international scientific meetings.

###

World Congress on Osteoporosis, Osteoarthritis & Musculoskeletal Diseases (WCO-IOF-ESCEO Prague 2026)

Held jointly by IOF and ESCEO, the Congress takes place in Prague, Czech Republic, April 16-19, 2026. WCO-IOF-ESCEO is the world’s largest annual forum for the presentation of clinical research and new advances in the prevention and management of bone, muscle and joint disorders, including skeletal rare disorders, sarcopenia and frailty. 
For complete information visit www.wco-iof-esceo.org  #OsteoCongress

About ESCEO

The European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO) is a non-profit organization, dedicated to a close interaction between clinical scientists dealing with rheumatic disorders, pharmaceutical industry developing new compounds in this field, regulators responsible for the registration of such drugs and health policymakers, to integrate the management of osteoporosis and osteoarthritis within the comprehensive perspective of health resources utilization. The objective of ESCEO is to provide practitioners with the latest clinical and economic information, allowing them to organize their daily practice, from an evidence-based medicine perspective, with a cost-conscious perception. www.esceo.org

About IOF

The International Osteoporosis Foundation (IOF) is the world’s largest nongovernmental organization dedicated to the prevention, diagnosis, and treatment of osteoporosis and related musculoskeletal diseases. Its members — including committees of leading scientific researchers and 349 patient, medical, and research organizations across 152 countries — work together to make fracture prevention and healthy mobility a global healthcare priority.

https://www.osteoporosis.foundation   @iofbonehealth